Fierce Pharma3d
Novo Nordisk offers cheaper Wegovy for all cash-paying patients at retail pharmacy
Novo Nordisk has quickly expanded its discounted Wegovy program, now offering all eligible cash-paying customers its popular ...
Novo Nordisk expands Wegovy $499-per-month offering
Novo Nordisk (NVO) announced updates to the Wegovy savings program, allowing all eligible cash-paying patients access to Wegovy injection 0.25 ...
Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy® savings offer
Novo Nordisk announced updates to the Wegovy® savings program, allowing all eligible cash-paying patients access to Wegovy® ...
Novo Nordisk Strikes $2B Deal for Obesity Drug
Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...
Nasdaq3d
Novo Nordisk Expands $499 Wegovy Savings Offer To All Cash-paying Patients
Till now, the reduced price offer was only available with NovoCare pharmacy. Wegovy injection is prescribed to reduce the risk of major cardiovascular events in adults with known heart disease and ...
NBC Chicago3d
Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure
Both results wiped significant value from Novo's share price as investors' hopes of finding a superior alternative to the company's existing Wegovy injection and rival Eli Lily's Zepbound ...
Morningstar3d
Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy® savings offer
allowing all eligible cash-paying patients access to Wegovy® (semaglutide) injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg at their local pharmacy for a reduced cost of $499 per month.